JP2016501877A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501877A5
JP2016501877A5 JP2015545481A JP2015545481A JP2016501877A5 JP 2016501877 A5 JP2016501877 A5 JP 2016501877A5 JP 2015545481 A JP2015545481 A JP 2015545481A JP 2015545481 A JP2015545481 A JP 2015545481A JP 2016501877 A5 JP2016501877 A5 JP 2016501877A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding portion
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015545481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501877A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/072467 external-priority patent/WO2014085749A2/en
Publication of JP2016501877A publication Critical patent/JP2016501877A/ja
Publication of JP2016501877A5 publication Critical patent/JP2016501877A5/ja
Ceased legal-status Critical Current

Links

JP2015545481A 2012-11-28 2013-11-29 クロストリジウム・ディフィシルに対する抗体 Ceased JP2016501877A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730790P 2012-11-28 2012-11-28
US61/730,790 2012-11-28
PCT/US2013/072467 WO2014085749A2 (en) 2012-11-28 2013-11-29 Antibodies against clostridium difficile

Publications (2)

Publication Number Publication Date
JP2016501877A JP2016501877A (ja) 2016-01-21
JP2016501877A5 true JP2016501877A5 (enExample) 2017-01-12

Family

ID=50828602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545481A Ceased JP2016501877A (ja) 2012-11-28 2013-11-29 クロストリジウム・ディフィシルに対する抗体

Country Status (9)

Country Link
US (1) US10117933B2 (enExample)
EP (1) EP2925362A4 (enExample)
JP (1) JP2016501877A (enExample)
CN (2) CN105025926B (enExample)
AU (2) AU2013352034B2 (enExample)
CA (1) CA2892973A1 (enExample)
HK (1) HK1216999A1 (enExample)
IL (1) IL239063A0 (enExample)
WO (1) WO2014085749A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3549949T5 (da) 2011-04-22 2024-09-02 Wyeth Llc Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014085749A2 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
USD952157S1 (en) 2020-06-19 2022-05-17 Qualigen Inc. Whole blood treatment cartridge
WO2022087021A1 (en) * 2020-10-20 2022-04-28 Fzata, Inc. Neutralized antibody and method of use thereof
CN112812189B (zh) * 2020-11-30 2022-05-17 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用
US20250059267A1 (en) * 2021-05-14 2025-02-20 Phenomic Ai Combination therapy for treatment of tumors comprising cancer-associated fibroblasts
CN116239683B (zh) * 2023-02-15 2024-12-27 兰州生物制品研究所有限责任公司 一种抗艰难梭菌毒素b的单克隆抗体及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5435945A (en) 1992-05-29 1995-07-25 Procor Sulphur Services, Inc. Method and apparatus for generating sulphur seed particles for sulphur granule production
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
DK1265928T3 (da) * 2000-01-27 2010-11-15 Medimmune Llc RSV-neutraliserende antistoffer med ultra høj affinitet
US8420353B2 (en) * 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004041857A2 (en) * 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
HRP20110599T1 (hr) * 2004-02-06 2011-10-31 University Of Massachusetts Antitijela protiv toksina clostridium difficile i njihove primjene
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007065037A2 (en) * 2005-12-02 2007-06-07 Curagen Corporation Antibodies against mmp-13 (collagenase-3) and uses thereof
EP2121756A4 (en) 2006-12-20 2011-08-31 Mmrglobal Inc ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
KR20100126760A (ko) * 2008-02-28 2010-12-02 쓰리엠 이노베이티브 프로퍼티즈 캄파니 클로스트리듐 디피실레 포자에 대한 항체 및 그 용도
AU2010215275B2 (en) * 2009-02-20 2016-03-31 Micropharm Limited Antibodies to Clostridium difficile toxins
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
EP2558493B1 (en) * 2010-04-15 2019-09-18 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of clostridium difficile-associated infection and disease
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
US9771416B2 (en) * 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CN103608464A (zh) * 2010-12-29 2014-02-26 卡恩基因公司 艰难梭菌抗原
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
JP6281163B2 (ja) * 2011-08-22 2018-02-21 エメルゲント バイオソリューションズ カナダ クロストリジウム・ディフィシレ抗体
BR112014006175B1 (pt) * 2011-09-16 2020-02-11 Ucb Pharma S.A. Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
US20150259402A1 (en) * 2012-10-19 2015-09-17 Evec Inc. Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof
WO2014085749A2 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
EP4079760A3 (en) * 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
WO2016130923A1 (en) * 2015-02-13 2016-08-18 Quanterix Corporation Immunoassays for diffrential detection of clostridium difficile
ES2870506T3 (es) * 2015-02-19 2021-10-27 Immune Biosolutions Inc Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos

Similar Documents

Publication Publication Date Title
JP2016501877A5 (enExample)
JP2023002706A (ja) 抗pdl1抗体、活性化可能抗pdl1抗体、およびその使用方法
JP2014529610A5 (enExample)
JP2017535257A5 (enExample)
JP2018512138A5 (enExample)
US12247075B2 (en) BTN3A binding proteins and uses thereof
JP2014511179A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
US20140212423A1 (en) Blood-brain barrier penetrating dual specific binding proteins
JP2009225799A5 (enExample)
JP2018532383A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2013506428A5 (enExample)
CN104903352A (zh) 多价结合蛋白组合物
JP2018502060A5 (enExample)
JP2010536384A5 (enExample)
JP2012518425A5 (enExample)
JP2015503909A5 (enExample)
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
TW201134487A (en) Therapeutic DLL4 binding proteins
JP2011207882A5 (enExample)
JP2013519364A5 (enExample)
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP2017507131A5 (enExample)
JP2015509960A5 (enExample)